Skip to main content
Premium Trial:

Request an Annual Quote

Bioanalytical Instrumentation Firm Creoptix Raises CHF 8M

NEW YORK — Creoptix, a Swiss developer of optical bioanalytic instrumentation, said today that it has raised CHF 8 million ($8.0 million) in a Series C financing round.

The round was led by Zürcher Kantonalbank's Swisscanto Invest and included existing investor Waters. In connection with the round, Swisscanto Invest has received a seat on Creoptix's board of directors.

Creoptix markets the waveguide interferometry-based WAVE system for studying molecular interactions in real time, with applications in membrane protein analysis in drug discovery and kinetic interaction studies in body fluids for biomarker and biotherapeutics development. The company said it will use the financing to bolster its commercial operations in Europe and the US, as well as to expand into new markets.

Creoptix said it has raised CHF 15 million since 2013.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more